Reviva Pharmaceuticals Holdings, Inc. (RVPH)
|Net Income (ttm)||-1.15M|
|Trading Day||January 26|
|Day's Range||8.72 - 8.91|
|52-Week Range||7.92 - 11.88|
Reviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Pharmaceuticals Holdings, Inc.
Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Tenzing Acquisition Corp.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Tenzing Acquisition Corp. with Reviva Pharmaceuticals, Inc.
New York, New York--(Newsfile Corp. - July 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who own Tenzing Acquisition Corp.
Reviva Pharmaceuticals Holdings, a clinical stage pharmaceutical company, develops therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, as well as for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. The company is based in Cupertino, California.
Dr. Laxminarayan Bhat
|Stock Exchange |
|Ticker Symbol |